B-cell Acute Lymphoblastic Leukemia Clinical Trials

120 clinical trials for B-cell Acute Lymphoblastic Leukemia across international registries, including 53 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) — RECRUITING · PHASE2
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) — RECRUITING · PHASE1
• Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol — RECRUITING · PHASE2
• A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia — RECRUITING · PHASE1
• Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• Study of Out of Specification for Tisagenlecleucel — RECRUITING · PHASE3
• Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL — RECRUITING · PHASE1
• Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL — RECRUITING · PHASE1
• A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia — RECRUITING · PHASE3
• AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia — RECRUITING · PHASE1
• Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) — RECRUITING · PHASE1
• Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies — RECRUITING · PHASE1
• CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions — RECRUITING
• UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL — RECRUITING · PHASE1
• CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies — RECRUITING · PHASE1
• Co-administration of CART22-65s and huCART19 for B-ALL — RECRUITING · PHASE1
• Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients — RECRUITING · NA
• Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial — RECRUITING · PHASE1
• CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction — RECRUITING · NA
• A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab — RECRUITING
• Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia — RECRUITING · PHASE1
• Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL — RECRUITING · PHASE1
• Study of YK012 in B-cell Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) — RECRUITING · PHASE1
• JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) — RECRUITING · PHASE1
• Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL — RECRUITING · PHASE1
• CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL — RECRUITING · PHASE1
• Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL — RECRUITING · PHASE1
• ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML — RECRUITING · PHASE1
• Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) — RECRUITING · PHASE1
• Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol — RECRUITING · PHASE2
• AN INTERNATIONAL PILOT STUDY OF CHEMOTHERAPY AND TYROSINE KINASE INHIBITORS WITH BLINATUMOMAB IN PATIENTS WITH NEWLY-DIOGNOSED PHILADELPHIA CHROMOSOME-POSITIVE OR ABL-CLASS PHILADELPHIA CHROMOSOME-LIKE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA — RECRUITING
• A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) — RECRUITING · PHASE1
• Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL) — RECRUITING · NA
• The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL — RECRUITING · PHASE2
• Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia — RECRUITING · NA
• Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL — RECRUITING · PHASE2
• Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies — RECRUITING · PHASE1
• Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. — RECRUITING · PHASE2
• Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia — RECRUITING
• Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma — RECRUITING · PHASE1
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL — RECRUITING · PHASE2
• CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol — RECRUITING · PHASE2
• Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL — RECRUITING · PHASE1
• Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT — RECRUITING · PHASE2

Refine this search